231 related articles for article (PubMed ID: 27550363)
1. Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.
Grooms TN; Vuong HR; Tyo KM; Malik DA; Sims LB; Whittington CP; Palmer KE; Matoba N; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2016 Nov; 60(11):6518-6531. PubMed ID: 27550363
[TBL] [Abstract][Full Text] [Related]
2. pH-responsive delivery of Griffithsin from electrospun fibers.
Tyo KM; Duan J; Kollipara P; Dela Cerna MVC; Lee D; Palmer KE; Steinbach-Rankins JM
Eur J Pharm Biopharm; 2019 May; 138():64-74. PubMed ID: 29698714
[TBL] [Abstract][Full Text] [Related]
3. Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro.
Tyo KM; Vuong HR; Malik DA; Sims LB; Alatassi H; Duan J; Watson WH; Steinbach-Rankins JM
Int J Pharm; 2017 Oct; 531(1):118-133. PubMed ID: 28797967
[TBL] [Abstract][Full Text] [Related]
4. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
[TBL] [Abstract][Full Text] [Related]
5. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.
O'Keefe BR; Vojdani F; Buffa V; Shattock RJ; Montefiori DC; Bakke J; Mirsalis J; d'Andrea AL; Hume SD; Bratcher B; Saucedo CJ; McMahon JB; Pogue GP; Palmer KE
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6099-104. PubMed ID: 19332801
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of poly(lactic-co-glycolic acid) and poly(dl-lactide-co-ε-caprolactone) electrospun fibers for the treatment of HSV-2 infection.
Aniagyei SE; Sims LB; Malik DA; Tyo KM; Curry KC; Kim W; Hodge DA; Duan J; Steinbach-Rankins JM
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():238-251. PubMed ID: 28024582
[TBL] [Abstract][Full Text] [Related]
7. Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections.
Vuong HR; Tyo KM; Steinbach-Rankins JM
J Vis Exp; 2017 Oct; (128):. PubMed ID: 29155732
[TBL] [Abstract][Full Text] [Related]
8. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.
Levendosky K; Mizenina O; Martinelli E; Jean-Pierre N; Kizima L; Rodriguez A; Kleinbeck K; Bonnaire T; Robbiani M; Zydowsky TM; O'Keefe BR; Fernández-Romero JA
Antimicrob Agents Chemother; 2015 Dec; 59(12):7290-8. PubMed ID: 26369967
[TBL] [Abstract][Full Text] [Related]
9. Rapid-Release Griffithsin Fibers for Dual Prevention of HSV-2 and HIV-1 Infections.
Tyo KM; Lasnik AB; Zhang L; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229493
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
Mori T; O'Keefe BR; Sowder RC; Bringans S; Gardella R; Berg S; Cochran P; Turpin JA; Buckheit RW; McMahon JB; Boyd MR
J Biol Chem; 2005 Mar; 280(10):9345-53. PubMed ID: 15613479
[TBL] [Abstract][Full Text] [Related]
11. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide.
Emau P; Tian B; O'keefe BR; Mori T; McMahon JB; Palmer KE; Jiang Y; Bekele G; Tsai CC
J Med Primatol; 2007 Aug; 36(4-5):244-53. PubMed ID: 17669213
[TBL] [Abstract][Full Text] [Related]
12. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate.
Kouokam JC; Huskens D; Schols D; Johannemann A; Riedell SK; Walter W; Walker JM; Matoba N; O'Keefe BR; Palmer KE
PLoS One; 2011; 6(8):e22635. PubMed ID: 21829638
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the antiviral activity of the microbicide candidate griffithsin and its tandemers derivatives against different modes of HIV-1 transmission.
Alexandre K; Malatji K; Mulaudzi T
Virology; 2020 May; 544():12-20. PubMed ID: 32174510
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.
Tyo KM; Lasnik AB; Zhang L; Mahmoud M; Jenson AB; Fuqua JL; Palmer KE; Steinbach-Rankins JM
J Control Release; 2020 May; 321():84-99. PubMed ID: 32035194
[TBL] [Abstract][Full Text] [Related]
15. Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.
Moulaei T; Alexandre KB; Shenoy SR; Meyerson JR; Krumpe LR; Constantine B; Wilson J; Buckheit RW; McMahon JB; Subramaniam S; Wlodawer A; O'Keefe BR
Retrovirology; 2015 Jan; 12():6. PubMed ID: 25613831
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.
Crakes KR; Herrera C; Morgan JL; Olstad K; Hessell AJ; Ziprin P; LiWang PJ; Dandekar S
J Int AIDS Soc; 2020 Oct; 23(10):e25628. PubMed ID: 33073530
[TBL] [Abstract][Full Text] [Related]
17. Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P; Albecka A; Belouzard S; Vercauteren K; Verhoye L; Wychowski C; Leroux-Roels G; Palmer KE; Dubuisson J
Antimicrob Agents Chemother; 2011 Nov; 55(11):5159-67. PubMed ID: 21896910
[TBL] [Abstract][Full Text] [Related]
18. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
[TBL] [Abstract][Full Text] [Related]
19. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.
Kagiampakis I; Gharibi A; Mankowski MK; Snyder BA; Ptak RG; Alatas K; LiWang PJ
Antimicrob Agents Chemother; 2011 Jan; 55(1):264-75. PubMed ID: 20956603
[TBL] [Abstract][Full Text] [Related]
20. The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.
Xue J; Gao Y; Hoorelbeke B; Kagiampakis I; Zhao B; Demeler B; Balzarini J; Liwang PJ
Mol Pharm; 2012 Sep; 9(9):2613-25. PubMed ID: 22827601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
